MK-677, also called ibutamoren, is an orally active growth hormone secretagogue. Although commonly grouped with peptides, it is a non-peptide small molecule that mimics aspects of ghrelin signalling.
Human studies demonstrate hormonal and body-composition changes, and research into healthy ageing, athletic recovery and muscle applications continues to grow.

Ibutamoren is a ghrelin-receptor agonist studied for effects on growth hormone secretion and related clinical outcomes. Oral activity distinguishes it from many injectable secretagogues.
A physician-supervised programme ensures product identity, purity, strength and dosing are properly managed.
Ibutamoren activates the growth hormone secretagogue receptor, increasing growth hormone secretion and IGF-1. Ghrelin-related signalling can also increase appetite.
Increased fat-free mass does not necessarily represent improved muscle function. Fluid changes and other components of lean tissue can influence body-composition measurements.
A randomised trial in healthy older adults found increased growth hormone, IGF-1 and fat-free mass. It did not demonstrate corresponding improvements in strength or function, or a significant reduction in visceral fat.
These findings illustrate why hormone levels and body-composition measurements are tracked alongside overall wellbeing during a supervised programme.
Reported concerns include increased appetite, oedema, muscle discomfort, increased fasting glucose and reduced insulin sensitivity. Long-term benefit-risk remains uncertain.
Physician consultation comes first, particularly for people with diabetes, cardiovascular disease or fluid-retention concerns, and medical monitoring continues throughout treatment.
It is a non-peptide small molecule, although it is often discussed alongside peptide-based growth hormone secretagogues.
Ibutamoren is offered within physician-supervised programmes, with realistic expectations set during consultation.
A trial in older adults found increased fat-free mass, and research continues into strength and functional outcomes.
Yes. Human studies have identified increased fasting glucose and reduced insulin sensitivity, making metabolic assessment particularly important.
This information, including but not limited to texts, images, graphics, labels, ingredients, indications, potential benefits, and other materials contained on this website are for informational purposes only. No part of this website is intended to be a substitute for professional medical advice, treatment, or diagnosis. Always seek the advice of your physician or other professional healthcare provider, particularly before starting a new regimen for the first time.
Speak with our medical team about your health goals. We will help you understand which options are supported by evidence and appropriate for your situation.